Related Experiment Video
Updated: May 11, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
Pneumocystis pneumonia associated with human immunodeficiency virus
Robert F Miller1, Laurence Huang, Peter D Walzer
1Research Department of Infection and Population Health, University College London, London WC1E 6JB, UK. robert.miller@ucl.ac.uk
Pneumocystis pneumonia (PCP) remains a common presentation of AIDS, even with available treatments. Further research is needed to evaluate diagnostic biomarkers and the optimal timing for starting antiretroviral therapy (ART) in patients with PCP.
Area of Science:
- Infectious Diseases
- Mycology
- Immunology
Background:
- Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis fungi.
- PCP is a frequent AIDS-defining illness, particularly in Africa, despite advances in prophylaxis and antiretroviral therapy (ART).
Purpose of the Study:
- To review the current understanding of Pneumocystis pneumonia (PCP) in the context of HIV/AIDS.
- To highlight diagnostic challenges and treatment strategies for PCP.
Main Methods:
- Literature review of diagnostic and treatment guidelines for PCP.
- Analysis of PCP epidemiology and outcomes in the era of ART.
Main Results:
- PCP diagnosis relies on methods like bronchoalveolar lavage as Pneumocystis cannot be cultured.
- Trimethoprim-sulfamethoxazole is the primary treatment for PCP.
- PCP-related mortality is around 10-12% even with ART, and optimal ART initiation timing is unclear.
Conclusions:
- PCP continues to be a significant clinical challenge in HIV-infected individuals.
- Further evaluation of diagnostic biomarkers and ART initiation strategies is crucial for improving PCP patient outcomes.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
11:19Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses
Published on: May 4, 2015
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pneumonia II: Pathophysiology
Atypical Pneumonia